We therefore performed sequential ECV quantification using CMR T1 mapping and evaluated the prognostic impact of its changes on outcome in treated, as well as treatment-naïve, transthyretin (ATTR) and light chain (AL) amyloidosis patients. The gene discussed is TTR; the disease is amyloidosis.